Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: Rationale for preventative measures

Current Medicinal Chemistry

Volumn 15, Issue 28, 2008, Pages 2991-2999

  De Lorenzo, F ^a   Collot Teixeira, S ^b   Boffito, M ^a,c   Feher, M ^a   Gazzard, B ^a,c   McGregor, J L ^b,d  

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Crusaid Research Institute   (United Kingdom)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Atherosclerosis; Coronary heart disease; HIV; Hyperlipidaemia; Lipodystrophy; Macrophages; Statins

Indexed keywords

ALPHA TOCOPHEROL; AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LIPID; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL OBESITY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; MACROPHAGE FUNCTION; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; THROMBOSIS; ANIMAL; CHEMISTRY; COMORBIDITY; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; HYPERLIPIDEMIA; LIPODYSTROPHY; MACROPHAGE; METABOLISM; METHODOLOGY; TREATMENT OUTCOME;

ANIMALS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHEMISTRY, PHARMACEUTICAL; COMORBIDITY; CORONARY DISEASE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; LIPODYSTROPHY; MACROPHAGES; TREATMENT OUTCOME;

EID: 58149384809     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986708786848668     Document Type: Review

References (78)

1. Friis-Moller, N.; Reiss, P.; Sabin, C.A.; Weber, R.; Monforte, A.; El-Sadr, W.; Thiebaut, R.; De Wit, S.; Kirk, O.; Fontas, E.; Law, M.G.; Phillips, A.; Lundgren, J.D. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med., 2007, 356, 1723-35.
2. Friis-Moller, N.; Sabin, C.A.; Weber, R.; d'Arminio Monforte, A.; El-Sadr, W.M.; Reiss, P.; Thiebaut, R.; Morfeldt, L.; De Wit, S.; Pradier, C.; Calvo, G.; Law, M.G.; Kirk, O.; Phillips, A.N.; Lundgren, J.D. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med., 2003, 349, 1993-2003.
3. Stein, J.H. Cardiovascular risks of antiretroviral therapy. N. Engl. J. Med., 2007, 356, 1773-5.
4. Vittecoq, D.; Escaut, L.; Chironi, G.; Teicher, E.; Monsuez, J.J.; Andrejak, M.; Simon, A. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS, 2003, 17 (Suppl 1), S70-6.
5. Law, M.G.; Friis-Moller, N.; El-Sadr, W.M.; Weber, R.; Reiss, P.; D'Arminio Monforte, A.; Thiebaut, R.; Morfeldt, L.; De Wit, S.; Pradier, C.; Calvo, G.; Kirk, O.; Sabin, C.A.; Phillips, A.N.; Lundgren, J.D. the use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: Comparison with observed events in the D:A:D Study. HIV Med., 2006, 7, 218-30.
6. Mondy, K.; Overton, E.T.; Grubb, J.; Tong, S.; Seyfried, W.; Powderly, W.; Yarasheski, K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin. Infect. Dis., 2007, 44, 726-34.
7. Hadigan, C.; Meigs, J.B.; Corcoran, C.; Rietschel, P.; Piecuch, S.; Basgoz, N.; Davis, B.; Sax, P.; Stanley, T.; Wilson, P.W.; D'Agostino, R.B.; Grinspoon, S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis., 2001, 32, 130-9.
8. Miller, K.D.; Jones, E.; Yanovski, J.A.; Shankar, R.; Feuerstein, I.; Falloon, J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet, 1998, 351, 871-5.
9. Yarasheski, K.E.; Tebas, P.; Sigmund, C.; Dagogo-Jack, S.; Bohrer, A.; Turk, J.; Halban, P.A.; Cryer, P.E.; Powderly, W.G. Insulin resistance in HIV protease inhibitor-associated diabetes. J. Acquir. Immune Defic. Syndr., 1999, 21, 209-16.
10. Carr, A.; Law, M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J. Acquir. Immune. Defic. Syndr., 2003, 33, 571-6.
11. Bernasconi, E.; Boubaker, K.; Junghans, C.; Flepp, M.; Furrer, H.J.; Haensel, A.; Hirschel, B.; Boggian, K.; Chave, J.P.; Opravil, M.; Weber, R.; Rickenbach, M.; Telenti, A. Abnormalities in body fat distribution in HIV-infected patients treated with antiretroviral drugs: The Swiss Cohort Study. J. Acquir. Immune. Defic. Syndr., 2002, 31, 50-5.
12. Lichtenstein, K.A.; Delaney, K.M.; Armon, C.; Ward, D.J.; Moorman, A.C.; Wood, K.C.; Holmberg, S.D. Incidence of and risk factors for lipodystrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr., 2003, 32, 48-56.
13. Barbaro, G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. Curr. Pharm. Des., 2007, 13, 2208-13.
14. Falutz, J.; Allas, S.; Blot, K.; Potvin, D.; Kotler, D.; Somero, M.; Berger, D.; Brown, S.; Richmond, G.; Fessel, J.; Turner, R.; Grinspoon, S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N. Engl. J. Med., 2007, 357, 2359-70
15. Hirosumi, J.; Tuncman, G.; Chang, L.; Gorgun, C.Z.; Uysal, K.T.; Maeda, K.; Karin, M.; Hotamisligil, G.S. A central role for JNK in obesity and insulin resistance. Nature, 2002, 420, 333-6.
16. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 2003, 112, 1796-808.
17. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; Chen, H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 2003, 112, 1821-30.
18. Wellen, K.E.; Hotamisligil, G.S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest., 2003, 112, 1785-8.
19. Lyon, C.J.; Law, R.E.; Hsueh, W.A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology, 2003, 144, 2195-200.
20. Trayhurn, P.; Wood, I.S. Br. J. Nutr., 2004, 92, 347-55.
21. Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet, 2005, 365, (9468), 1415-28.
22. Suganami, T.; Nishida, J.; Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2062-8.
23. Grunfeld, C.; Pang, M.; Doerrler, W.; Shigenaga, J.K.; Jensen, P.; Feingold, K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunedeficiency syndrome. J. Clin. Endocrinol. Metab., 1992, 74, 1045-52.
24. Riddler, S.A.; Smit, E.; Cole, S.R.; Li, R.; Chmiel, J.S.; Dobs, A.; Palella, F.; Visscher, B.; Evans, R.; Kingsley, L.A. Impact of HIV infection and HAART on serum lipids in men. JAMA, 2003, 289, 2978-82.
25. van der Valk, M.; Kastelein, J.J.; Murphy, R.L.; van Leth, F.; Katlama, C.; Horban, A.; Glesby, M.; Behrens, G.; Clotet, B.; Stellato, R.K.; Molhuizen, H.O.; Reiss, P. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS, 2001, 15, 2407-14.
26. Mujawar, Z.; Rose, H.; Morrow, M.P.; Pushkarsky, T.; Dubrovsky, L.; Mukhamedova, N.; Fu, Y.; Dart, A.; Orenstein, J.M.; Bobryshev, Y.V.; Bukrinsky, M.; Sviridov, D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS. Biol., 2006, 4, (11), e365.
27. Tsiodras, S.; Mantzoros, C.; Hammer, S.; Samore, M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch. Intern. Med., 2000, 160, 2050-6.
28. Cameron, D.W.; Heath-Chiozzi, M.; Danner, S.; Cohen, C.; Kravcik, S.; Maurath, C.; Sun, E.; Henry, D.; Rode, R.; Potthoff, A.; Leonard, J. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The advanced HIV Disease Ritonavir Study Group. Lancet, 1998, 351, 543-9.
29. Liang, J.S.; Distler, O.; Cooper, D.A.; Jamil, H.; Deckelbaum, R.J.; Ginsberg, H.N.; Sturley, S.L. HIV protease inhibitors project apolipoprotein B from degradation by the proteosome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med., 2001, 7, 1327-31.
30. Tarr, P.E.; Taffe, P.; Bleiber, G.; Furrer, H.; Rotger, M.; Martinez, R.; Hirschel, B.; Battegay, M.; Weber, R.; Vernazza, P.; Bernasconi, E.; Darioli, R.; Rickenbach, M.; Ledergerber, B.; Telenti, A. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis., 2005, 191, 1419-26.
31. Serghides, L.; Nathoo, S.; Walmsley, S.; Kain, K.C. CD36 deficiency induced by antiretroviral therapy. AIDS, 2002, 16, 353-8.
32. Dressman, J.; Kincer, J.; Matveev, S.V.; Guo, L.; Greenberg, R.N.; Guerin, T.; Meade, D.; Li, X.A.; Zhu, W.; Uittenbogaard, A.; Wilson, M.E.; Smart, E.J. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J. Clin. Invest., 2003, 111, 389-97.
33. Munteanu, A.; Ricciarelli, R.; Zingg, J.M. HIV protease inhibitors-induced atherosclerosis: Prevention by alpha-tocopherol. IUBMB Life, 2004, 56, 629-31.
34. Munteanu, A.; Zingg, J.M.; Ricciarelli, R.; Azzi, A. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alphatocopherol. Free Radic. Biol. Med., 2005, 38, 1047-56.
35. Bradshaw, E.L.; Li, X.A.; Guerin, T.; Everson, W.V.; Wilson, M.E.; Bruce-Keller, A.J.; Greenberg, R.N.; Guo, L.; Ross, S.A.; Smart, E.J. Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C. Am. J. Physiol. Cell. Physiol., 2006, 291, C1271-8.
36. Meroni, L.; Riva, A.; Morelli, P.; Galazzi, M.; Mologni, D.; Adorni, F.; Galli, M. Increased CD36 expression on circulating monocytes during HIV infection. J. Acquir. Immune. Defic. Syndr., 2005, 38, 310-3.
37. Meroni, L.; Giacomet, V.; Morelli, P.; Erba, P.; Galazzi, M.; Riva, A.; Vigano, A.; Galli, M. Increased CD36 expression in vertically human immunodeficiency virus-infected children unrelated to antiretroviral therapy. Pediatr. Infect. Dis. J., 2005, 24, 576-7.
38. Goudriaan, J.R.; Dahlmans, V.E.; Teusink, B.; Ouwens, D.M.; Febbraio, M.; Maassen, J.A.; Romijn, J.A.; Havekes, L.M.; Voshol, P.J. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. J. Lipid Res., 2003, 44, 2270-7.
39. Libby, P.; Ridker, P.M. Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am. J. Med., 2004, 116 (Suppl 6A), 9S-16S.
40. Ridker, P.M. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001, 103, 1813-8.
41. Jialal, I.; Devaraj, S. The role of C-reactive protein activation of nuclear factor kappa-B in the pathogenesis of unstable angina. J. Am. Coll. Cardiol., 2007, 49, 195-7.
42. Noursadeghi, M.; Miller, R.F. Clinical value of C-reactive protein measurements in HIV-positive patients. Int. J. STD AIDS, 2005, 16, 438-41.
43. Feldman, J.G.; Goldwasser, P.; Holman, S.; DeHovitz, J.; Minkoff, H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J. Acquir. Immune. Defic. Syndr., 2003, 32, (2), 210-4.
44. Lau, B.; Sharrett, A.R.; Kingsley, L.A.; Post, W.; Palella, F.J.; Visscher, B.; Gange, S.J. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch. Intern. Med., 2006, 166, 64-70.
45. Hunt, P.W.; Martin, J.N.; Sinclair, E.; Bredt, B.; Hagos, E.; Lampiris, H.; Deeks, S.G. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis., 2003, 187, 1534-43.
46. Hazenberg, M.D.; Stuart, J.W.; Otto, S.A.; Borleffs, J.C.; Boucher, C.A.; de Boer, R.J.; Miedema, F.; Hamann, D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active retroviral therapy (HAART). Blood, 2000, 95, (1), 249-55.
47. Hellerstein, M.; Hanley, M.B.; Cesar, D.; Siler, S.; Papageorgopoulos, C.; Wieder, E.; Schmidt, D.; Hoh, R.; Neese, R.; Macallan, D.; Deeks, S.; McCune, J.M. Directly measured kinetics of ciruclating T lymphocytes in normal and HIV-1 infected humans. Nat. Med., 1999, 5, 83-9.
48. Hansson, G.K.; Jonasson, L.; Lojsthed, B.; Stemme, S.; Kocher, O.; Gabbiani, G. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis, 1988, 72, 135-41.
49. Zhou, X.; Nicoletti, A.; Elhage, R.; Hansson, G.K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation, 2000, 102, 2919-22
50. Frostegard, J.; Ulfgren, A.K.; Nyberg, P.; Hedin, U.; Swedenborg, J.; Andersson, U.; Hansson, G.K. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis, 1999, 145, 33-43.
51. Rusnati, M.; Presta, M. HIV-1 Tat protein and endothelium: From protein/ cell interaction to AIDS-associated pathologies. Angiogenesis, 2002, 5, 141-51.
52. Paladugu, R.; Fu, W.; Conklin, B.S.; Lin, P.H.; Lumsden, A.B.; Yao, Q.; Chen, C. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg., 2003, 38, 549-6.
53. Martin, S.; Tesse, A.; Hugel, B.; Martinez, M.C.; Morel, O.; Freyssinet, J.M.; Andriantsitohaina, R. Shed membrane proteins from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation, 2004, 109, 1653-9.
54. Sipsas, N.V.; Sfikakis, P.P. Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection. Clin. Diagn. Lab. Immunol., 2004, 11, 996-1001.
55. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 1998, 97, 425-8.
56. Blankenberg, S.; Barbaux, S.; Tiret, L. Adhesion molecules and atherosclerosis. Atherosclerosis, 2003, 170, 191-203.
57. Ridker, P.M.; Hennekens, C.H.; Roitman-Johnson, B.; Stampfer, M.J.; Allen, J. Plasma concentration of soluble intercellular adhesion module 1 and risks of future myocardial infarction in apparently healthy men. Lancet, 1998, 351, 88-92.
58. de Lorenzo, F.; Feher, M.; Martin, J.; Collot-Teixeira, S.; Dotsenko, O.; McGregor, J.L. Statin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr. Med. Chem., 2006, 13, 3385-93.
59. Jain, M.K.; Ridker, P.M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov., 2005, 4, 977-87.
60. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; McCabe, C.H.; Pfeffer, M.A.; Braunwald, E. C-reactive protein levels and outcomesafter statin therapy. N. Engl. J. Med., 2005, 352, 20-8.
61. Ridker, P.M.; Wilson, P.W.; Grundy, S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation, 2004, 109, 2818-25.
62. Hurlimann, D.; Chenevard, R.; Ruschitzka, F.; Flepp, M.; Enseleit, F.; Bechir, M.; Kobza, R.; Muntwyler, J.; Ledergerber, B.; Luscher, T.F.; Noll, G.; Weber, R. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease-inhibitor containing anti-retroviral therapy: A randomised double blind crossover trial. Heart, 2006, 92, (1), 110-2.
63. Sudano, I.; Spieker, L.E.; Noll, G.; Corti, R.; Weber, R.; Luscher, T.F. Cardiovascular disease in HIV infection. Am. Heart J., 2006, 151, (6), 1147-55.
64. Massy, Z.A.; Keane, W.F.; Kasiske, B.L. Inhibition of the mevalonate pathway: Benefits beyond cholesterol reduction? Lancet, 1996, 347, 102-3.
65. Sposito, A.C.; Chapman, M.J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1524-34.
66. Liao, J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest., 2002, 110, 285-8.
67. Smith, D.A.; Galin, I. Statin therapy for native and periinterventional coronary heart disease. Curr. Mol. Med., 2006, 6, 589-602.
68. Hayden, M.S.; Ghosh, S. Signalling to NFkappa-B. Genes Dev., 2004, 18, 2195-224.
69. Wong, B.; Lumma, W.C.; Smith, A.M.; Sisko, J.T.; Wright, S.D.; Cai, T.Q. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol., 2001, 69, 959-62.
70. Feinberg, M.W.; Lin, Z.; Fisch, S.; Jain, M.K. An emerging role for Krüppel-like factors in vascular biology. Trends Cardiovasc. Med., 2004, 14, 241-6.
71. Plutzky, J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J. Am. Coll. Cardiol., 2003, 42, 1764-6.
72. Lin, Z.; Kumar, A.; SenBanerjee, S.; Staniszewski, K.; Parmar, K.; Vaughan, D.E.; Gimbrone, M.A., Jr.; Balasubramanian, V.; Garcia-Cardena, G.; Jain, M.K. Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ. Res., 2005, 96, e48-57.
73. SenBanerjee, S.; Lin, Z.; Atkins, G.B.; Greif, D.M.; Rao, R.M.; Kumar, A.; Feinberg, M.W.; Chen, Z.; Simon, D.I.; Luscinskas, F.W.; Michel, T.M.; Gimbrone, M.A. Jr.; Garcia-Cardena, G.; Jain, M.K. KLF2 is a novel transcriptional regulator of endothelial proinflammatory activation. J. Exp. Med., 2004, 199, 1305-15.
74. Parmar, K.M.; Nambudiri, V.; Dai, G.; Larman, H.B.; Gimbrone, M.A. Jr.; Garcia-Cardena, G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J. Biol. Chem., 2005, 280, 26714-9.
75. Landrier, J.F.; Thomas, C.; Grober, J.; Duez, H.; Percevault, F.; Souidi, M.; Linard, C.; Staels, B.; Besnard, P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome-activated receptor-alpha-dependent. J. Biol. Chem., 2004, 279, 45512-8.
76. Zelvyte, I.; Dominaitiene, R.; Crisby, M.; Janciauskiene, S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastin in response to lipoproteins in human monocytes in vitro. Pharmacol. Res., 2002, 45, 147-54.
77. Liuzzo, G.; Santamaria, M.; Biasucci, L.M.; Narducci, M.; Colafrancesco, V.; Porto, A.; Brugaletta, S.; Pinnelli, M.; Rizzello, V.; Maseri, A.; Crea, F. Persistent activation of nuclear factor kappa-B signalling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopoylsaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. J. Am. Coll. Cardiol., 2007, 49, 185-94.
78. Istvan, E. S.; Deisendorf, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292, 1160-4